Treatment of the insulin resistance syndrome
OwnerDavid Albert Fryburg, Earl Michael Gibbs +1inventors
InventorsDavid Albert Fryburg, Earl Michael Gibbs, Nandan Parmanand Koppiker
Life of this patent
Estimating the term…
Abstract
Use of a selective cGMP PDE5 inhibitor or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricaemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.
Claims72
A method of treating the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or composition thereof, wherein the insulin resistance syndrome means the concomitant existence in said mammal of two or more of:
- dyslipidemia;
- hypertension;
- type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes;
- hyperuricaemia and/or gout;
- a pro-coagulant state;
- atherosclerosis;
- or truncal obesity.
A method of treating the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor or a pharmaceutically acceptable salt, solvate or pharmaceutical composition thereof.
A method of treating the insulin resistance syndrome in a mammal comprising administering to said mammal an effective amount of a selective cGMP PDE5 inhibitor in combination with one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors;
- one or more insulin sensitising agents;
- and one or more hypoglycaemic agents.
A method of treating type 2 diabetes mellitus in a mammal comprising administering to said mammal an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
A method of treating type 2 diabetes mellitus in a mammal comprising administering to said mammal an effective amount of sildenafil citrate in combination with one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors one or more insulin sensitising agents;
- and one or more hypoglycaemic agents.
A method of treating impaired glucose tolerance (IGT) in a mammal comprising administering to said mammal an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor or a pharmaceutical composition thereof.
A method of treating of impaired glucose tolerance (IGT) in a mammal comprising administering to said mammal an effective amount of sildenafil citrate in combination with one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors;
- one or more insulin sensitising agents;
- and one or more hypoglycaemic agents.
A method of treating insulin resistance (IR) in a mammal comprising administering to said mammal an effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor or a pharmaceutical composition thereof.
A method of treating of insulin resistance (IR) in a mammal comprising administering to said mammal an effective amount of sildenafil citrate in combination with one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors;
- one or more insulin sensitising agents;
- and one or more hypoglycaemic agents.
A kit containing a treatment for the insulin resistance syndrome, wherein the insulin resistance syndrome means the concomitant existence in said mammal of two or more of:
- dyslipidemia;
- hypertension;
- type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes;
- hyperuricaemia and/or gout;
- a pro-coagulant state;
- atherosclerosis;
- or truncal obesity comprising:
- a) a therapeutically effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor and a pharmaceutically acceptable carrier in a first unit dosage form;
- b) a therapeutically effective amount of one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors;
- one or more insulin sensitising agents;
- and one or more hypoglycaemic agents nd a pharmaceutically acceptable carrier in a second unit dosage form;
- and
- c) a container for containing said first and second dosage forms.
A kit containing a treatment for type 2 diabetes mellitus comprising:
- a) a therapeutically effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor and a pharmaceutically acceptable carrier in a first unit dosage form;
- b) a therapeutically effective amount of one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors;
- one or more insulin sensitising agents;
- and one or more hypoglycaemic agents nd a pharmaceutically acceptable carrier in a second unit dosage form;
- and
- c) a container for containing said first and second dosage forms.
A kit containing a treatment for impaired glucose tolerance (IGT) comprising:
- a) a therapeutically effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor and a pharmaceutically acceptable carrier in a first unit dosage form;
- b) a therapeutically effective amount of one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors;
- one or more insulin sensitising agents;
- and one or more hypoglycaemic agents nd a pharmaceutically acceptable carrier in a second unit dosage form;
- and
- c) a container for containing said first and second dosage forms.
A kit containing a treatment for insulin resistance comprising:
- a) a therapeutically effective amount of a selective pyrazolopyrimidinone cGMP PDE5 inhibitor and a pharmaceutically acceptable carrier in a first unit dosage form;
- b) a therapeutically effective amount of one or more further components selected from one or more of:
- protein kinase inhibitors;
- and or one or more activators or AMP-activated protein kinase;
- and/or one or more weight loss agents;
- and/or insulin;
- and/or one or more PPAR-gamma agonists;
- and/or one or more PPAR-alpha agonists;
- and/or one or more dual PPAR-alpha/PPAR-gamma agonists;
- one or more sorbitol dehydrogenase inhibitors;
- one or more aldose reductase inhibitors;
- one or more insulin sensitising agents;
- and one or more hypoglycaemic agents nd a pharmaceutically acceptable carrier in a second unit dosage form;
- and
- c) a container for containing said first and second dosage forms.
Dependencies are inferred from the claim text.